What is recombinant tissue‑type plasminogen activator (rtPA) and how is it used in the management of acute ischemic stroke, including dosing examples?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 19, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

What is rtPA in Stroke Management?

rtPA (recombinant tissue-type plasminogen activator), also known as alteplase, is a thrombolytic medication that converts plasminogen to plasmin, which dissolves blood clots by cleaving fibrin—it is the only FDA-approved treatment for acute ischemic stroke and must be administered within specific time windows to improve functional outcomes. 1

Mechanism of Action

rtPA works by converting inactive plasminogen into active plasmin, which then promotes thrombolysis by breaking down fibrin in blood clots that are occluding cerebral arteries during acute ischemic stroke 2. This restores blood flow to ischemic brain tissue, potentially salvaging neurons and improving neurological outcomes.

Dosing Regimen

The FDA-approved dose is 0.9 mg/kg (maximum 90 mg total) administered intravenously: 3, 1

  • 10% of total dose given as initial IV bolus over 1 minute
  • Remaining 90% infused over 60 minutes

Dosing Example:

  • 70 kg patient: 63 mg total dose

    • 6.3 mg IV bolus over 1 minute
    • 56.7 mg IV infusion over 60 minutes
  • 100 kg patient: 90 mg total dose (maximum)

    • 9 mg IV bolus over 1 minute
    • 81 mg IV infusion over 60 minutes

Time Windows for Administration

Within 3 Hours (Class I, Level A Evidence)

rtPA should be offered to all eligible patients who can be treated within 3 hours of symptom onset—this is the strongest recommendation with the best evidence for improving functional outcomes. 3, 2 The number needed to treat is 8.3, meaning for every 8-9 patients treated, one additional patient achieves minimal or no disability 2.

3 to 4.5 Hours (Class I, Level B Evidence)

rtPA should be considered for carefully selected patients between 3-4.5 hours after symptom onset, with additional exclusion criteria: 3

Additional exclusions for the 3-4.5 hour window:

  • Age >80 years
  • Taking oral anticoagulants (regardless of INR)
  • NIHSS score >25
  • Imaging showing ischemic injury >1/3 of MCA territory
  • History of both prior stroke AND diabetes mellitus

Critical caveat: As of current FDA labeling, rtPA is only approved within 3 hours; the 3-4.5 hour window represents off-label use based on ECASS III trial data 2.

Key Inclusion Criteria

  • Diagnosis of acute ischemic stroke with measurable neurological deficit
  • Age ≥18 years
  • Treatment can be initiated within appropriate time window
  • CT or MRI excludes intracranial hemorrhage 3

Absolute Contraindications

Do not administer rtPA if any of the following are present: 3

  • Current intracranial hemorrhage
  • Subarachnoid hemorrhage
  • History of intracranial hemorrhage
  • Intracranial neoplasm, AVM, or aneurysm
  • Recent intracranial/intraspinal surgery
  • Significant head trauma or prior stroke in previous 3 months
  • Active internal bleeding
  • Suspected aortic dissection
  • Platelet count <100,000/mm³
  • Current anticoagulation with INR >1.7 or PT >15 seconds
  • Heparin within 48 hours with elevated aPTT
  • Direct thrombin or factor Xa inhibitors within 48 hours
  • Blood pressure >185/110 mmHg despite treatment
  • Blood glucose <50 mg/dL (2.7 mmol/L)

Critical Implementation Requirements

Door-to-needle time must be ≤60 minutes from hospital arrival (Class I, Level A) 3. Earlier treatment within any time window produces better outcomes—every minute counts.

The effectiveness of rtPA requires institutional systems for safe administration 2. This includes:

  • Rapid CT/MRI availability
  • Experienced stroke team
  • Neurological monitoring capabilities
  • ICU-level care for post-thrombolysis management

Major Risk: Symptomatic Intracranial Hemorrhage

The primary risk is symptomatic intracranial hemorrhage (sICH), occurring in approximately 6% of treated patients 2. The number needed to harm is 17 within the 3-hour window 4. Despite this risk, 90-day mortality is not increased with rtPA treatment 3, 2.

To minimize bleeding risk:

  • Strict adherence to inclusion/exclusion criteria
  • Avoid intramuscular injections
  • No anticoagulants or antiplatelets for 24 hours post-treatment
  • Blood pressure control <185/110 mmHg before and <180/105 mmHg after treatment
  • Close neurological monitoring

Common Pitfalls to Avoid

  1. Do not delay treatment for "minor" or "improving" symptoms—these patients can still benefit, and symptoms may worsen 5

  2. Do not withhold rtPA based on CT hypoattenuation extent—analysis shows no significant interaction between baseline CT changes and treatment benefit 6

  3. Do not use other thrombolytic agents as substitutes—only alteplase (rtPA) has proven efficacy for stroke 3, 7

  4. Do not add other medications to rtPA infusion 1

  5. Do not treat beyond 4.5 hours unless in a clinical trial setting—evidence does not support benefit 8

Post-Administration Management

Monitor closely for:

  • Neurological deterioration (repeat CT immediately if suspected hemorrhage)
  • Blood pressure (maintain <180/105 mmHg)
  • Signs of bleeding
  • Hypersensitivity reactions 1

Aspirin can be started 24 hours after rtPA administration if follow-up imaging excludes hemorrhage 7, 8.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.